Replies to post #83384 on Biotech Values

[DewDiligence]

VVUS:

…Qnexa uses the perfect combination of both generics and probably has a patent for the combination. Could be a problem down the road given the rigid obviousness guidelines patents are assessed with these days.

The problem for VVUS is not the potential invalidation of the “use” patent but rather that VVUS has no practical way to enforce the patent. Whom would VVUS sue if doctors write prescriptions for the two generic constituents?